Category: Parkinson's Disease: Cognitive functions
Objective: To assess specific cognitive biomarkers to increase the sensibility for the diagnosis of Prodromal Parkinson’s disease (pPD) that could help to identify these patients.
Background: pPD criteria feature a high specificity but a lack of sensitivity. Global cognitive decline is a risk marker for pPD but with low positive likelihood ratio. Thus, searching for new biomakers with a higher impact to optimize the identification of the prodromal phase of Parkinson’s disease (PD) is crucial.
Method: We evaluated a cohort of patients with pPD, PD with less than five years of disease evolution and healthy controls (HC). A detail clinical evaluation and a large neuropsychological battery were performed. The neuropsychological assessment included Montreal Cognitive Assessment (MoCA), Parkinson`s Disease Cognitive Rating Scale (PD-CRS) and Frontal Lobe Assessment (FAB). ANOVA tests was applied to assess differences among groups and Tukey test for multiple comparisons
Results: We evaluated a cohort of patients with pPD, PD with less than five years of disease evolution and healthy controls (HC). A detail clinical evaluation and a large neuropsychological battery were performed. The neuropsychological assessment included Montreal Cognitive Assessment (MoCA), Parkinson`s Disease Cognitive Rating Scale (PD-CRS) and Frontal Lobe Assessment (FAB). ANOVA tests was applied to assess differences among groups and Tukey test for multiple comparisons
Conclusion: In addition to global cognitive deficits, pPD patients could present with selective frontal dysfunction. Thus, frontal functioning should be deeply assessed as a putative biomarker with a higher sensitivity in prodromal phases of PD.
To cite this abstract in AMA style:
SJM. Jesús Maestre, LMD. Muñoz Delgado, ACG. Castellano Guerrero, MSE. San Eufrasio, AAG. Adarmes Gómez, DMG. Macías García, PFR. Franco Rosado, BV. Villarreal, BB. Benitez, CPC. Perez Calvo, FCG. Carrillo García, JMR. Martín Rodríguez, PMR. Mir Rivera. Frontal dysfunction as a cognitive biomarker in prodromal Parkinson’s disease [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/frontal-dysfunction-as-a-cognitive-biomarker-in-prodromal-parkinsons-disease/. Accessed October 12, 2024.« Back to 2024 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/frontal-dysfunction-as-a-cognitive-biomarker-in-prodromal-parkinsons-disease/